Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colon cancer in the phase\u00e2 $ 3 FLARE CRC test

.Completing passions.S.K.: Supply as well as Various Other Possession Interests: Iylon, Lutris, MolecularMatch, Navire. Consulting or even Advisory Duty: AbbVie, Amal Rehabs, AstraZeneca/MedImmune, Bayer Wellness, Bicara Therapies, Boehringer Ingelheim, Boston Ma Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Venture BioMedicines, Blaze Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Medical Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Music Drugs, Lilly, Lutris, Merck, Mirati Therapies, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Therapy, Servier, Xilis. Research Backing: Amgen (Inst), Assortment BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Health (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Work: In The Past Pfizer. Sell and also Other Possession Enthusiasms: Pfizer. J.P.: Work: In The Past Pfizer. Inventory and also Other Ownership Claims: Pfizer. F.C.: Consulting or Advisory Duty: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Research Backing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or even Advisory Task: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Investigation Funding: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Function: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Pharmaceutical, Terumo. H.S.W.: Consulting or Advisory Duty: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapeutics, Erytech Pharma, Incyte, Merck KGaA, Oaktree Lifestyle Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, County, Sirtex Medical, Takeda (Hutchinson Medication), Zymeworks. Analysis Financing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Investigation Financing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Drug (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Pharmaceutical (Inst). H.S.: Work: Pfizer. Supply and also Other Possession Claims: Pfizer. X.Z.: Work: Pfizer. Stock as well as Other Ownership Stakes: Pfizer. Patents, Royalties, Various Other Trademark: Johns Hopkins Educational Institution. P.H.: Employment: Pfizer. Stock as well as Other Ownership Claims: Pfizer. T.X.: Work: Pfizer. Sell and Various Other Possession Claims: Pfizer. R.Y.: Consulting or Advisory Job: Array BioPharma/Pfizer, Mirati Therapeutics, Zai Lab, Amgen. Study Funding: Range BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapy (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or even Advisory Part: Range BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Rehabs, MSD, NeoPhore, Novartis, Ona Therapeutics, Orion Medical, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapy, Seagen Inc., Servier, Taiho Drug, Tessa Therapy, TheraMyc. Other Partnership: Amgen, Selection Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Cells Study UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de la Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Contra el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health KGaA, MJH Lifestyle Sciences, MSD, Merus, Mirati, Novartis, Oniria Rehabs, PeerView Principle for Medical Education And Learning, Pfizer, PharmaMar, Physicansu00e2 $ Education Source, Sanofi-Aventis, Servier, Taiho Pharmaceutical.